UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/597,991	06/21/2007	Eric James Wall	CHM-021M	8880
38155 HASSE & NES	7590 10/20/200 BITT LLC	EXAMINER		
8837 CHAPEL SUITE C	SQUARE DRIVE	PRICE, NATHAN R		
CINCINNATI,	ОН 45249	ART UNIT	PAPER NUMBER	
			3763	
			MAIL DATE	DELIVERY MODE
			10/20/2009	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Advisory Action Before the Filing of an Appeal Brief

Application No.	Applicant(s)	
10/597,991	WALL ET AL.	
Examiner	Art Unit	

	TWATTE TROL	0700
The MAILING DATE of this communication app	ears on the cover sheet with the o	correspondence address
THE REPLY FILED <u>05 October 2009</u> FAILS TO PLACE THIS	APPLICATION IN CONDITION FOI	R ALLOWANCE.
1. The reply was filed after a final rejection, but prior to or or application, applicant must timely file one of the following application in condition for allowance; (2) a Notice of Application (RCE) in compliance with 37 periods:	replies: (1) an amendment, affidavi real (with appeal fee) in compliance	it, or other evidence, which places the with 37 CFR 41.31; or (3) a Request
a) The period for reply expiresmonths from the mailin	g date of the final rejection.	
b) The period for reply expires on: (1) the mailing date of this a no event, however, will the statutory period for reply expire Examiner Note: If box 1 is checked, check either box (a) or	later than SIX MONTHS from the mailing (b). ONLY CHECK BOX (b) WHEN THE	g date of the final rejection.
MONTHS OF THE FINAL REJECTION. See MPEP 706.07 Extensions of time may be obtained under 37 CFR 1.136(a). The date have been filed is the date for purposes of determining the period of exunder 37 CFR 1.17(a) is calculated from: (1) the expiration date of the set forth in (b) above, if checked. Any reply received by the Office late may reduce any earned patent term adjustment. See 37 CFR 1.704(b NOTICE OF APPEAL	on which the petition under 37 CFR 1.1 dension and the corresponding amount shortened statutory period for reply origi r than three months after the mailing dat	of the fee. The appropriate extension fee inally set in the final Office action; or (2) as
2. ☐ The Notice of Appeal was filed on A brief in com	pliance with 37 CFR 41.37 must be	filed within two months of the date of
filing the Notice of Appeal (37 CFR 41.37(a)), or any extension Notice of Appeal has been filed, any reply must be filed value. AMENDMENTS	ension thereof (37 CFR 41.37(e)), to	avoid dismissal of the appeal. Since a
 The proposed amendment(s) filed after a final rejection, (a) They raise new issues that would require further co (b) They raise the issue of new matter (see NOTE below 	onsideration and/or search (see NO	
(c) They are not deemed to place the application in be appeal; and/or	tter form for appeal by materially red	
(d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a))		ected claims.
4. The amendments are not in compliance with 37 CFR 1.1		mpliant Amendment (PTOL-324).
5. Applicant's reply has overcome the following rejection(s		,
 Newly proposed or amended claim(s) would be a non-allowable claim(s). 	llowable if submitted in a separate,	
7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is pro The status of the claim(s) is (or will be) as follows: Claim(s) allowed: Claim(s) objected to: Claim(s) rejected: Claim(s) withdrawn from consideration:		ll be entered and an explanation of
AFFIDAVIT OR OTHER EVIDENCE		
 The affidavit or other evidence filed after a final action, be because applicant failed to provide a showing of good an was not earlier presented. See 37 CFR 1.116(e). 		
9. The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar	overcome <u>all</u> rejections under appea	al and/or appellant fails to provide a
10. ☐ The affidavit or other evidence is entered. An explanation REQUEST FOR RECONSIDERATION/OTHER	on of the status of the claims after e	ntry is below or attached.
The request for reconsideration has been considered by See Continuation Sheet.	ut does NOT place the application in	n condition for allowance because:
12. ☐ Note the attached Information <i>Disclosure Statement</i>(s).13. ☐ Other:	(PTO/SB/08) Paper No(s)	
/Nicholas D Lucchesi/ Supervisory Patent Examiner, Art Unit 3763		

Continuation of 11. does NOT place the application in condition for allowance because:

- 1. Applicant's arguments filed October 5, 2009 have been fully considered but they are not persuasive.
- 2. Applicant argues on page 7 of the Remarks that "a person of ordinary skill in the art would not understand that extreme exceptions (individuals with high pain thresholds and injection areas experiencing low pain) qualify the entire range of needle sizes disclosed in Miskinyar as being capable of administering a painless needle insertion". However, Examiner notes that Applicant is still, with the characterization of Examiner's interpretation as referencing "extreme" exceptions, interpreting the claim limitation too narrowly. Nowhere in the claim is the function of the device limited to use on a human. One of ordinary skill in the art at the time the invention was made would understand that pain threshold would not only vary from person to person and from injection location to injection location, but also between species. Applicant cites the portion of the specification which ties painless injection to the needle diameter. However, Examiner relies upon Woehr and not Minskinyar for teaching needle diameter.
- 3. Regarding Applicant's arguments on pages 7 through 8 of the Remarks in reference to the teachings of Woehr, Examiner maintains that Woehr does suggest to one of ordinary skill in the art at the time the invention was made that needle sizes in the range claimed would be useful. The fact that he discloses other needle sizes as well outside of the range claimed does not detract from the teaching of the needle sizes within the claimed range. Woehr shows that one having ordinary skill in the art at the time the invention was made would understand that these needle diameters would be available and ideally suited for the purposes taught by Woehr in par. 0079.
- 4. Regarding Applicant's arguments on pages 8 through 9 of the Remarks that the "retraction spring 102" of Miskinyar is "misnomered" and "cannot retract the needle from its second extended position to a third position". Applicant has misunderstood the operation of the Miskinyar apparatus, and is misinterpreting the "force required to advance the piston". Spring 102 is clearly delineated by Miskinyar as a "retraction spring 102" (col. 5, ln. 28). Furthermore, it would be necessary for the force of the retraction spring to be less than the force required to *advance* the piston so that the device would be capable of actuating. The force required to advance the piston is the force required to move piston 100 through medication chamber 98 (see fig. 8). Initial actuation of the device of fig. 8 results in spring 128 moving the entire needle/medicament reservoir assembly distally so that needle 94 penetrates the tissue. After penetration, continued force from 128 moves piston 100 distally to eject medication from chamber 98. Once such actuation is complete, the force exerted by *retraction* spring 102 is greater than distally directed force of spring 128, and retraction of the entire needle/piston apparatus is effected.
- 5. Examiner addressed the remainder of Applicant's arguments fully in the previous Office Action..